Letter on the application of the “one substance one assessment” principle in the case of BPA and TBBP-A
Position Paper
14 Feb 2021

Related items

Position Paper
26 Jun 2026

CBAM extension: get implementation right before expanding scope

The Carbon Border Adjustment Mechanism (CBAM) will test whether the EU can address carbon leakage while keeping investment in Europe. As implementation of the CBAM advances, companies face costs and reporting duties under rules that are still taking shape. Preventing carbon leakage matters. However, the CBAM should work in practice before scope extension is considered. Moving too soon could place burdens on companies and disrupt value chains, with consequences for investment and trade. The focus should be on avoiding measures that introduce further uncertainty and extending proposed safeguards in the Temporary Decarbonisation Fund beyond 2027. Learn how to shape the CBAM so it prevents carbon leakage while maintaining competitiveness. 

Energy
Read more
Read more about CBAM extension: get implementation right before expanding scope
Publication
25 Jun 2026

Recommendations to the Irish Presidency of the Council of the EU

Ireland will assume the Presidency of the Council of the European Union in the second half of 2026 at a decisive moment for Europe’s competitiveness agenda. With the EU seeking to advance simplification, strengthen the Single Market and shape the next Multiannual Financial Framework, the Presidency will have a critical role to play in turning ambition into action. Its programme spans competitiveness, values and security. However, none of these priorities can succeed without a strong economy that fosters innovation and growth. In this context, AmCham EU’s Recommendations to the Irish Presidency of the Council of the EU sets out concrete actions to advance a competitive and resilient EU economy. These proposals aim to help shape Europe into an attractive place for businesses to invest, operate and grow.

Presidency
Read more
Read more about Recommendations to the Irish Presidency of the Council of the EU
News
24 Jun 2026

A medical milestone, made in Denmark

Pfizer selected Denmark as the site of the largest vaccine registry study ever undertaken, demonstrating how Europe can attract world-leading life sciences investment when the right conditions are in place. Beginning in 2024, Pfizer partnered with researchers at the Center for Translational Cardiology and Pragmatic Randomized Trials at Herlev-Gentofte Hospital in Copenhagen to assess whether its respiratory syncytial virus vaccine could reduce hospitalisations in adults. Denmark’s innovation-friendly environment, national digital mailbox eBoks and world-class health registries enabled researchers to invite almost the entire adult population to take part, helping recruit more than 500,000 participants. Study materials were made available online, allowing participants to provide informed consent from home, while health registries supported comprehensive tracking and analysis. This milestone shows how strong public-private collaboration and a supportive policy framework can help Europe deliver clinical research at scale and improve health outcomes for citizens. Read the full story on Invested in Europe

Healthcare
Read more
Read more about A medical milestone, made in Denmark